Cardiovascular outcomes with SGLT-2 inhibitors and GLP-1 receptor agonist in Asians with type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcome trials-Reference-Cited by-同舟云学术

Cardiovascular outcomes with SGLT-2 inhibitors and GLP-1 receptor agonist in Asians with type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcome trials

Published:2020-07 Issue:4 Volume:14 Page:715-722
ISSN:1871-4021
Container-title:Diabetes & Metabolic Syndrome: Clinical Research & Reviews
language:en
Short-container-title:Diabetes & Metabolic Syndrome: Clinical Research & Reviews

Author:

Singh Awadhesh Kumar^ORCID,Singh Ritu

Publisher

Elsevier BV

Subject

General Medicine,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference50 articles.

1. Genetic predisposition to type 2 diabetes among Asian Indians;Radha;Indian J Med Res,2007

2. Obesity in South Asia: phenotype, morbidities, and mitigation;Misra;Curr Obes Rep,2019

3. Diabetes in Asia;Ramachandran;Lancet,2010

4. The metabolic syndrome in South Asians: continuing escalation & possible solutions;Misra;Indian J Med Res,2007

5. Adiposity and hyperinsulinemia in Indians are present at birth;Yajnik;J Clin Endocrinol Metab,2002

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ethnic disparities in cardiovascular and renal responses to canagliflozin between Asian and White patients with type 2 diabetes mellitus: A post hoc analysis of the CANVAS Program;Diabetes, Obesity and Metabolism;2023-11-30

2. Effect of empagliflozin on cardiac remodelling in South Asian and non-South Asian individuals: insights from the EMPA-HEART CardioLink-6 randomised clinical trial;BMC Cardiovascular Disorders;2023-11-15

3. Does race/ethnicity influence the impact of new glucose-lowering agents on cardiovascular outcomes? a comparison between Asian versus White patients;Annals of Translational Medicine;2022-12

4. Mechanisms of GLP‒1 Receptor Agonists on the Cardio-Renal Protective Effects;Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics;2022-11-30

5. Cardio-Renal Benefits of GLP-1 Receptor Agonists vs. SGLT-2 Inhibitors in Type 2 Diabetes: Are They Juxtaposed?;Clinical Diabetology;2022-08-31